Abstract. Insulin and the insulinlike growth factors (IGF-I and IGF-II) are members of a family of hormones that regulate the metabolism and growth of many tissues. Cultured HEP-G2 cells (a minimal deviation human hepatoma) have insulin receptors and respond to insulin by increasing their glycogen metabolism.
Introduction
Insulin and insulinlike growth factors belong to a family of polypeptide hormones that exhibit a similar spectrum of biological activities and have a high degree of sequence homology (1) (2) (3) (4) (5) . However, insulin and the insulinlike growth factors are distinct immunologically, and their relative potencies in eliciting various cellular effects differ (6, 7) . Typically, insulin has more potent short-term metabolic effects, whereas the insulinlike growth factors (IGFs)' have potent long-term growth effects (3, 6, 8) . The insulinlike growth factors include IGF-I (also called somatomedin C) and IGF-II (which is similar to multiplication stimulation activity). These factors are two separate hormones and IGF-I is under the control of growth hormone (6, 9, 10) .
In addition to having sequence homology, these hormones can interact to some extent with each other's receptors. Both the insulin and IGF-I receptors are oligomeric tetramers with two alpha and two beta subunits linked by sulphydryl bonds (1 1-14) . In contrast, the IGF-II receptor has a relative molecular weight of -240,000 and has no discernible subunit structure (I 1, 13). While the subunits of the insulin and IGF-I receptors are similar, they are reported to have slightly different molecular weights (15) and to differ antigenically (16) (17) (18) (19) . Insulin and IGF-I can react with each other's receptors, but with relative differences in affinity ranging from 100-to 1,000-fold (4, 13) . Also, IGF-II can react with both the IGF-I receptor and the insulin receptor (4, 13) . However, IGF-I, but not insulin, can react readily with the IGF-II receptor.
Two approaches have been used to distinguish whether an effect of insulin on target cells is occurring either via its own receptor or via the IGF-I receptor. One approach is to use purified hormones and analyze the sensitivity of the doseresponse curves. In most instances, insulin acts on its own receptor at picomolar or nanomolar concentrations, whereas it acts on the IGF-I receptor at micromolar concentrations (18, 20) . The other approach is to use antibodies specific to the insulin receptor that either mimic or inhibit the action of insulin but not IGF-I (18, 19) . In one report, an Fab fragment of a polyclonal antibody was used to distinguish between insulin and IGF effects on human fibroblasts (18) .
Recently, we reported the production of a species-specific mouse monoclonal anti-receptor antibody that is directed towards the human insulin receptor (19, 21) . This antibody reacts with the insulin binding site and competitively blocks insulin binding; moreover, this antibody antagonizes the biological actions of insulin (21) . Since this antibody reacts only weakly with IGF-I receptors, and does not react with the IGF-II receptor (19) , it can be used to probe whether an effect of insulin occurs via its own receptor or via an IGF receptor.
A major function of insulin is to regulate the hepatic metabolism of glycogen, but the relative roles of insulin and insulinlike growth factor on this function are unknown. Recently, it has been reported that cultured HEP-G2 hepatoma cells, obtained from a minimal deviation human hepatoma (22) unlabeled ligand as indicated. At specified times, the incubation medium was removed, and the cell layer was washed twice at 4°C with 154 mM sodium chloride with 10 mM Tris (hydroxymethyl)aminomethane, pH 7.8 (Tris-saline). The cells were then scraped off each dish and collected with 0.9 ml of the aforementioned Trissaline into 12 X 75-mm glass test tubes, followed by the addition of 0.1 ml I N NaOH. The radioactivity associated with the cells was measured in a 'y-scintillation counter. An aliquot of the incubation medium was also counted to determine the total radioactivity in the medium. After counting, the protein content of the solubilized cells was measured (26) . Nonspecific binding was determined by incubating cells with the same concentrations of labeled hormone plus 10 JAM unlabeled insulin (for '251-insulin), either 100 uM unlabeled insulin or 100 nM unlabeled mixed IGF (for '25I-IGF-I), and 100 nM unlabeled mixed IGF (for '251-IGF-II), respectively.
'251-Hormone degradation. '251-Insulin and '25I-IGF-I and '251-IGF-II degradation in the incubation media was determined by precipitability in 10% trichloroacetic acid (TCA). In addition, '25I-insulin degradation was also measured by the ability of medium '251-insulin to bind to human IM-9 lymphocytes (27).
Incorporation of (31Hglucose into glycogen. Assay of insulin-stimulated incorporation of [3H]glucose into glycogen was a modification of that described by Hofmann et al. (28) . Monolayer HEP-G2 cell cultures were incubated with 4 uCi of D[I-3H]glucose) for 2 h. After incubation, cells were rinsed twice with Tris-saline at 4°C. 1 ml of 30% KOH with 2 mg/ml carrier glycogen was then added followed by a 30-min incubation at 37°C. The solubilized mixture plus another 1 2. The subsequent data for mixed IGF concentrations were corrected for the degree of purity and the molarity of the material was calculated using a molecular weight of 7,500 for the IGFs. ml KOH-rinse were transferred to glass tubes, and the mixture was boiled for 30 min or until clear. After cooling to 4VC, glycogen was precipitated from I ml of the suspension by adding 2.3 ml of 95% ethanol. The precipitate was pelleted at 2,000 g, washed with 70% ethanol, dissolved in water, and counted for radioactivity in Liquiscint in a liquid scintillation counter. Blanks were obtained by immediately processing incubated cells 6 s after addition of labeled glucose. Protein content was measured by the method of Lowry et al. (29) .
Statistics. The t test for paired observations was used for the evaluation of statistical differences.
Results '25I-Insulin binding studies. Fig. 1, upper) . After 120 min of incubation, 7% of the '25I-insulin was degraded as measured by the TCA method, and 23% was degraded by the IM-9 receptor binding method.
The specificity of insulin binding to HEP-G2 cells was assessed by competitive binding experiments using unlabeled native insulin, proinsulin, and unrelated hormones (Fig. 2) . Native insulin one-half maximally inhibited '25I-insulin binding at 0.26±0.09 nM (mean±SEM, n = 5). Proinsulin was 1% as potent. In contrast, cholecystokinin and growth hormone had negligible effects. Of interest was the observation that prolactin at 1 MM inhibited binding by 20 (Fig. 3) . When the insulin dose-response curves were evaluated, the effect of the hormone was biphasic (Fig. 3) . The first phase of stimulation occurred over the range of 1-100 pM (one-half maximal concentration 4-9 pM), and the second phase occurred over the range of 100 pM-100 nM (one-half maximal concentration 0.7 to 1 nM). The effect of insulin at low concentrations (first phase) accounted for 20-30% ofthe maximal insulin effect. Proinsulin induced a parallel stimulation of glucose incorporation but was only 1% as potent as insulin. Growth hormone and cholecystokinin were without effect. Prolactin in concert with 3. In this paper the accumulation of '2ll-hormone by HEP-G2 cells is referred to as binding. This process includes both the initial interaction of hormone with the cell surface as well as the internalization of the hormone and subsequent processing. its small effect on insulin binding had a small stimulating effect on glycogen metabolism. Influence of monoclonal anti-insulin receptor antibody. Anti-receptor antibody competitively inhibited the binding of '25I-insulin to HEP-G2 cells. A detectable effect was seen at 100 pM and a maximal effect was seen at 100 nM (Fig. 4 A) . At this concentration, however, only 75% of the specific insulin binding was inhibited. Normal mouse IgG had little or no effect.
To determine whether the residual '25I-insulin binding that was not inhibited by anti-receptor antibody was via either the insulin receptor or another receptor, HEP-G2 cells were first preincubated with 100 nM anti-receptor antibody. Next the cells were incubated with '251-insulin, and either unlabeled insulin or IGF (Fig. 4 B) . IGF was found to be more potent than insulin itself in inhibiting '251-insulin binding in the presence of anti-receptor antibody.
When 100 nM anti-receptor antibody was added with insulin, the antibody completely inhibited the first phase of insulin stimulation of [3H]glucose incorporation into glycogen (Fig. 5) . In contrast, the antibody was without effect on the second phase of stimulated glucose incorporation. Normal mouse IgG was without effect on either phase.
To study the effects of the antibody further, increasing concentrations of antibody were added to two concentrations of insulin: 100 pM (sufficient to maximally stimulate the first phase of[3H]glucose incorporation) and 100 nM (sufficient to stimulate the second phase) (Fig. 6 ). High concentrations of the antibody (100 nM) inhibited the stimulation induced by 100 pM insulin but were ineffective on the effect of 100 nM insulin. Normal mouse IgG was without effect on either concentration of insulin.
IGF binding studies. The prior studies of insulin binding
and action suggested that insulin may have been interacting in part with a receptor other than the insulin receptor. Accordingly, the binding of 80 pM '251I-IGF-I and '251I-IGF-II to HEP-G2 cells was then studied. Total binding of '251I-IGF-I was one-half maximal within 10 min of incubation, reached a maximal value of 11% per mg protein at 60 min of incubation, and then a slight decrease in binding was observed (Fig. 7) . '25I-IGF-II bound with a similar time course but to a lesser degree (maximal value of 7% per mg protein) than '25I-IGF-I. Nonspecific binding (in the presence of 100 nM partially purified IGF for labeled IGF-II, and 100 ,M insulin for labeled IGF-I) was <17% (IGF-I) and 26% (IGF-II) of total hormone binding, respectively. Degraded '23I-IGF-I and '2'I-IGF-II slowly appeared in the incubation medium (Fig. 7) . After 120 min of incubation, only 5 and 4% of the IGF-I and IGF-II, respectively, was degraded by the TCA method.
The abilities of IGF, insulin, anti-receptor antibody, and normal mouse IgG to compete with '25I-IGF-I binding were studied (Fig. 8) . Mixed IGF one-half maximally inhibited binding at 3.1±0.6 nM. Insulin also inhibited binding, but was 7% as active as IGF. Proinsulin was considerably less potent than insulin (data not shown). Anti-receptor antibody had weak effects and inhibited only at the highest dose tested (100 nM); however, at this concentration, normal IgG also inhibited '5I-IGF-I binding.
IGF also inhibited '25I-IGF-II binding (Fig. 8) . In contrast to studies with '23I-IGF-I, neither insulin, anti-receptor antibody, nor normal IgG had an inhibitory effect on '251-IGF-II binding.
Effects of IGF on [3HMglucose incorporation into glycogen.
Mixed IGF stimulated [3H]glucose incorporation into glycogen (Fig. 9) ; a one-half maximal effect was seen at 0.3 nM. The effect of this IGF preparation, however, was not inhibited by preincubation with 100 nM anti-receptor antibody. Highly purified IGF-I and IGF-II were then studied and both hormones alone also stimulated [3H]glucose incorporation into glycogen (Fig. 9, inset) ; IGF-I was slightly more potent than IGF-II.
When 10 nM of mixed IGF was added with 10 IAM insulin, the resultant stimulation of [3H]glucose incorporation was no different than when IGF was added alone (data not shown).
Discussion
Cell lines in tissue culture have been a valuable tool to study hormone action in liver-derived tissue. Rat hepatoma cells, previously used to investigate the mechanism of action of the glucocorticoids (30) (31) (32) , have also proved important in the study of insulin action. These cells have characteristics that are stable through many passages, and have been used to study enzyme regulation (28, (33) (34) (35) , insulin receptor phosphorylation and hormone-sensitive tyrosine kinase activity (36) , and second Regulation ofGlycogen Metabolism (28, (33) (34) (35) . In contrast to these studies with cultured rat hepatoma cells, relatively little is known about insulin receptors and insulin action in cultured human hepatoma cells.
In the present study, we investigated the regulation of glycogen metabolism in human hepatoma cells (HEP-G2) by both insulin and the insulinlike growth factors, IGF-I and IGF-II. In target cells, insulin and the insulinlike growth factors regulate both rapid metabolic effects and long-term growth promoting effects (3, 6, 38) . For many of the metabolic effects, insulin is a more potent agent; whereas for many of the longterm growth effects, the insulinlike growth factors are more potent agents (3, 6, 8 (46) , and chick myocytes (8) . This biphasic insulin dose-response curve for stimulation of [3H]glucose incorporation into glycogen was then analyzed with a species-specific monoclonal antibody directed at the binding portion of the human insulin receptor. As previously shown in human fibroblasts and adipocytes, this antibody is an antagonist of insulin action (21) . This antagonism also occurred in HEP-G2 cells, but only at insulin concentrations <100 pM. At higher insulin concentrations, the antibody was without effect. Therefore, this observation provided further evidence that, at lower concentrations, insulin was acting via the insulin receptor, whereas at higher concentrations insulin was acting via another receptor.
Competitive binding studies of '25I-insulin in HEP-G2 cells 4 . Insulin in certain instances can increase cell growth (38) (39) (40) , and IGF in certain instances can enhance metabolic functions (41) (42) (43) (44) (45) . with both native insulin and mouse anti-receptor antibody was in concert with these observations. Native insulin competitively inhibited the binding of '25I-insulin to its receptor.5 In contrast, the antibody was only able to inhibit 75% of '25I-insulin binding. These data also suggested that insulin was acting on two populations of receptors, only one of which was the insulin receptor. Moreover, the observation that IGF was more 5 . A nonlinear two-dimensional least squares analysis (four-parameter fit) (47) of the data in Fig. 2 Since insulin can react with the IGF-I receptor in other tissues, we studied the binding and biological effects of the insulinlike growth factors, IGF-I and IGF-II, on HEP-G2 cells. Both hormones specifically bound to these cells. The binding of I23-IGF-I, but not 251-IGF-II, was inhibited by high concentrations of insulin. This observation indicated, therefore, that in HEP-G2 cells insulin could interact with the IGF-I receptor. In HEP-G2 cells, the anti-receptor antibody was without effect on influencing the binding of either IGF-I or IGF-II. When studies of[3H]glucose incorporation into glycogen were studied, a mixture of IGF-I and IGF-II, as well as the pure hormones themselves, stimulated this function. Moreover, they did so at concentrations of 1 nM or less. However, unlike the effect of insulin, the effects of the IGFs on glycogen metabolism were not inhibited by anti-receptor antibody. These data indicated, therefore, that the IGFs were acting directly through their own receptors to regulate glycogen metabolism.
The biological significance of the metabolic regulation of liver glycogen metabolism by the insulinlike growth factors remains to be elucidated. In several other diverse cell types the IGFs at nanomolar concentrations or lower mediate the stimulation of glucose and amino acid transport, glycolysis, and glycogen synthesis (41) (42) (43) (44) (45) . These studies in liver and other tissues suggest, therefore, that in addition to their long-
